middle.news
Actinogen Medical Secures $4.77 Million Underwriting Ahead of Alzheimer’s Trial
10:12am on Tuesday 1st of September, 2026 AEST
•
Biotechnology
Read Story
Actinogen Medical Secures $4.77 Million Underwriting Ahead of Alzheimer’s Trial
10:12am on Tuesday 1st of September, 2026 AEST
Key Points
Full underwriting of unlisted options worth $4.77 million
Cash runway extended beyond late 2027
XanaMIA Alzheimer’s trial topline results expected November
Strong participant rollover to open-label extension
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Actinogen Medical (ASX:ACW)
OPEN ARTICLE